PGP and chronic kidney disease: Considering solubility, intestinal metabolism and P-GP-efflux transport mechanistically our model can be used to examine the influence of clinical aspects on cyclosporine dosing (such as non-immunosuppressive co-medication, nutrition, dyslipidemia and chronic kidney disease).